Epigenetic research reveals a potential treatment for CRC and other solid tumors

Elana Fertig named associate director for quantitative science at University of Maryland Greenebaum

Elana J. Fertig was named associate director for quantitative science at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.

March 21, 2025

Vol.51 No.11

In Brief

UCLA’s Theodore Scott Nowicki awarded $4.5M to advance cellular immunotherapies for solid tumors

Physician-scientist Theodore Scott Nowicki, an assistant professor-in-residence of pediatric hematology/oncology and microbiology, immunology, and molecular genetics at the David Geffen School of Medicine at UCLA, has been awarded a $4.5 million R37 MERIT Award to help improve the effectiveness of cellular therapies for solid tumors.

March 21, 2025

Vol.51 No.11

Clinical Roundup

Researchers identify HMGA1 as key driver in colon cancer development

A gene called high mobility group A1 may be the key that opens the door to the development of colon cancer, according to research led by investigators from the Johns Hopkins Kimmel Cancer Center, Johns Hopkins Department of Medicine, Johns Hopkins Department of Pathology and the Johns Hopkins Institute for Cell Engineering.

February 28, 2025

Vol.51 No.08

Clinical Roundup

In HER2+ CRC, anti-HER2 therapy may be less toxic alternative to EGFR inhibitors, phase II study finds

A phase II trial found that for patients with HER2+ metastatic colorectal cancer, dual HER2-inhibitor therapy can be a similarly efficacious but less toxic alternative to EGFR inhibitor therapy. Exploratory analysis suggests greater HER2 amplification in a tumor may be associated with greater clinical benefit of dual HER2 inhibitor vs EGFR inhibitor therapy.

January 31, 2025

Vol.51 No.04

In Brief

Johns Hopkins, Howard University reform collaboration to advance health equity

A collaborative effort to eliminate cancer health disparities among African Americans and other underserved populations in the Washington, DC, area is being reignited at the Johns Hopkins Kimmel Cancer Center and the Howard University Cancer Center.

January 10, 2025

Vol.51 No.01

In Brief

Stephen Baylin and Andrew Feinberg, of Johns Hopkins, win Technion’s Harvey Prize

Stephen BaylinAndrew FeinbergJohns Hopkins University School of Medicine and Johns Hopkins Kimmel Cancer Center researchers Stephen Baylin and Andrew Feinberg were awarded the 2022–2023 Harvey Prize in the field of Science and Technology by the Technion—Israel Institute of Technology.

December 13, 2024

Vol.50 No.46

Epigenetic research reveals a potential treatment for CRC and other solid tumors

YOU MAY BE INTERESTED IN

Elana Fertig named associate director for quantitative science at University of Maryland Greenebaum

UCLA’s Theodore Scott Nowicki awarded $4.5M to advance cellular immunotherapies for solid tumors

Researchers identify HMGA1 as key driver in colon cancer development

In HER2+ CRC, anti-HER2 therapy may be less toxic alternative to EGFR inhibitors, phase II study finds

Johns Hopkins, Howard University reform collaboration to advance health equity

Stephen Baylin and Andrew Feinberg, of Johns Hopkins, win Technion’s Harvey Prize

Renew today!

Subscriber content

Never miss an issue!

Login